Neurology · PANCE / PANRE

Ménière Disease

Inner-ear disorder of recurrent vertigo episodes, fluctuating low-frequency sensorineural hearing loss, tinnitus, and aural fullness.

Also known as: Meniere disease, endolymphatic hydrops, Ménière's disease

Overview

An idiopathic inner-ear disorder characterized by recurrent spontaneous episodes of vertigo lasting 20 minutes to 12 hours, accompanied by fluctuating low- to mid-frequency sensorineural hearing loss, tinnitus, and aural fullness in the affected ear (per Bárány Society / AAO-HNS criteria).

Epidemiology

Prevalence ~200 per 100,000. Onset typically between ages 40 and 60. Female predominance ~1.3:1. Bilateral involvement develops in 25-50% over years. Genetic predisposition (HLA associations, familial clusters).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Ménière Disease outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Family history of Ménière disease
  • Autoimmune inner ear disease
  • Migraine (overlap with vestibular migraine)
  • Allergic disorders
  • Possible viral or immune triggers

Pathophysiology

Endolymphatic hydrops — overaccumulation of endolymph distends the scala media and may rupture Reissner's membrane, producing acute potassium-induced injury to vestibular and cochlear hair cells. Etiology of hydrops is multifactorial: impaired endolymph absorption at the endolymphatic sac, autoimmune injury, ionic dysregulation, viral.

Clinical presentation

Symptoms

  • Episodic spontaneous vertigo lasting 20 min to 12 h (rarely up to 24 h)
  • Fluctuating low- to mid-frequency sensorineural hearing loss, typically unilateral
  • Roaring or low-pitched tinnitus that may worsen during episodes
  • Aural fullness or pressure in the affected ear
  • Nausea, vomiting, diaphoresis during episodes
  • Tumarkin 'otolithic crisis' drop attacks (sudden falls without warning, no LOC) in advanced disease

Signs / physical exam

  • Between attacks: exam often normal; later, persistent unilateral sensorineural hearing loss on audiogram
  • Spontaneous horizontal-torsional nystagmus during attacks (initially toward the affected ear in irritative phase, then away as the labyrinth fatigues)
  • Positive head-impulse test toward the affected side once vestibular function is reduced
  • Tuning fork tests (Weber, Rinne) consistent with unilateral SNHL

Classic findings

Recurrent spontaneous vertigo + unilateral low-frequency hearing loss + tinnitus + aural fullness.

Differential diagnosis

  • Vestibular migraine — Recurrent vertigo + migraine features (headache, photophobia, phonophobia, aura); hearing usually normal; responds to migraine prophylaxis
  • BPPV — Brief (seconds), positional vertigo with Dix-Hallpike; no hearing loss; treated with Epley maneuver
  • Vestibular neuritis — Single prolonged episode (days), no hearing loss, follows viral illness; unilateral caloric weakness
  • Labyrinthitis — Single episode with hearing loss; viral or bacterial; does not recur in classic form
  • Acoustic neuroma (vestibular schwannoma) — Progressive unilateral hearing loss + tinnitus; vertigo less prominent; MRI internal auditory canal diagnostic
  • Autoimmune inner ear disease — Bilateral, rapidly progressive sensorineural hearing loss; steroid-responsive
  • Perilymph fistula — Vertigo triggered by Valsalva, sneezing, or pressure changes; recent barotrauma or head injury

Diagnostic workup

Diagnostic criteria

Definite Ménière (Bárány/AAO-HNS 2015): ≥2 episodes of spontaneous vertigo lasting 20 min to 12 h + audiometrically documented low- to mid-frequency SNHL in the affected ear before, during, or after an episode + fluctuating aural symptoms (hearing loss, tinnitus, fullness) in the affected ear + no better explanation.

Labs

  • TSH, CBC, comprehensive metabolic panel, ANA, RPR, B12 (exclude metabolic/autoimmune mimics)
  • Lyme serology in endemic areas

Imaging

  • Pure-tone and speech audiometry — low/mid-frequency SNHL, often fluctuating; word recognition typically preserved early
  • MRI with gadolinium of internal auditory canals — exclude vestibular schwannoma and central pathology
  • Vestibular testing (videonystagmography, caloric, VEMPs) as indicated
  • Electrocochleography — elevated SP/AP ratio supports hydrops (not diagnostic alone)
  • Delayed gadolinium-enhanced MRI inner ear (specialized centers) can visualize hydrops

Treatment

First-line

  • Low-sodium diet (<2 g/day), caffeine and alcohol reduction, smoking cessation
  • Thiazide diuretic (hydrochlorothiazide, often combined with triamterene) or acetazolamide — to reduce endolymph volume
  • Vestibular suppressants for acute attacks: meclizine, dimenhydrinate, promethazine, lorazepam, prochlorperazine — limit to acute use; chronic use impairs vestibular compensation
  • Antiemetics (ondansetron, prochlorperazine) for nausea
  • Patient education and reassurance about benign nature of attacks
  • Vestibular rehabilitation for interictal imbalance

Persistent or refractory disease

  • Intratympanic corticosteroid (dexamethasone) injections — vestibular-sparing, may help hearing and vertigo
  • Intratympanic gentamicin — selectively ablates vestibular hair cells; controls vertigo at the cost of vestibular function (and some hearing risk)
  • Endolymphatic sac decompression — controversial benefit
  • Selective vestibular nerve section — preserves hearing; effective for vertigo control in serviceable-hearing patients
  • Labyrinthectomy — definitive vertigo control but destroys hearing; reserved for non-serviceable hearing

Migraine overlap

  • Trial migraine prophylaxis (propranolol, topiramate, amitriptyline, venlafaxine, magnesium) if vestibular migraine features present
  • Lifestyle measures: sleep, hydration, trigger avoidance

Second-line / adjunct

  • Betahistine — used widely outside the US; evidence mixed; not FDA-approved
  • Hearing aids for permanent SNHL; cochlear implant for severe bilateral hearing loss
  • Counseling and support groups for chronic disease impact

Complications

  • Progressive permanent sensorineural hearing loss
  • Bilateral involvement with cumulative hearing and balance disability
  • Drop attacks (Tumarkin crises) with fall-related injury
  • Chronic anxiety and depression
  • Loss of driving privileges and employment impact
  • Persistent disequilibrium between episodes

PANCE pearls

  • The combination of low-frequency SNHL with fluctuation is highly specific for Ménière — pure high-frequency loss argues for presbycusis or noise exposure.
  • Always image with MRI to exclude vestibular schwannoma before settling on Ménière, especially with unilateral hearing loss.
  • Vestibular migraine is the most common Ménière mimic — overlapping features include episodic vertigo, photophobia, and family history of migraine.
  • Intratympanic gentamicin trades vestibular function for vertigo control; counsel about persistent imbalance.
  • Avoid chronic vestibular suppressants — they prevent central compensation.

References

  • Bárány Society 2015 — Lopez-Escamez JA et al. Diagnostic criteria for Ménière's disease. J Vestib Res 2015;25:1-7.
  • AAO-HNS 2020 — Basura GJ et al. Clinical practice guideline: Ménière's disease. Otolaryngol Head Neck Surg 2020;162(2_suppl):S1-S55.

Practice Neurology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.